Pdt Partners, LLC Aveo Pharmaceuticals, Inc. Transaction History

Pdt Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.51 - $6.67 $38,139 - $72,476	-10,866 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.15 - $6.01 $34,227 - $65,304	10,866 New	10,866 $61,000
Q3 2021 Nov 15, 2021	SELL	$5.12 - $6.89 $190,464 - $256,308	-37,200 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.21 - $7.45 $58,783 - $70,521	-9,466 Reduced 20.28%	37,200 $245,000
Q1 2021 May 17, 2021	SELL	$5.97 - $15.28 $80,302 - $205,531	-13,451 Reduced 22.37%	46,666 $342,000

Q4 2020 Feb 16, 2021	SELL	$5.08 - $6.68 $8,747 - $11,502	-1,722 Reduced 2.78%	60,117 $347,000
Q3 2020 Nov 16, 2020	BUY	$4.16 - $6.26 $257,250 - $387,112	61,839 New	61,839 $367,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.